Accelerate your data science-driven drug discovery: Announcing QIAGEN Biomedical Knowledge Base

Author:

QIAGEN Digital Insights

Accelerate your data science-driven drug discovery: Announcing QIAGEN Biomedical Knowledge Base

You need biomedical relationships knowledge for innovative data- and analytics-driven drug discovery. Yet this knowledge is locked in thousands of publications and dozens of databases. Collecting, structuring and integrating this knowledge is a challenging task that is time- and resource-consuming. 

What if you could break knowledge silos and confidently power your drug discovery with data science using a high-quality and industry-validated source of structured and integrated biomedical relationships? 

We are excited to introduce QIAGEN Biomedical Knowledge Base, the leading knowledge about biomedical relationships, manually structured and integrated from thousands of sources by experts. It is a vast collection of diverse causal relationships between genes, diseases, drugs, targets, functions, toxicological processes and more, all of which are enriched with full context. QIAGEN Biomedical Knowledge Base delivers high-quality data ideally suited for major data science-driven drug discovery applications. These include knowledge graph construction and analysis, analytics- and artificial intelligence (AI)-driven target identification and drug repositioning, development of target, disease and drug intelligence portals, disease subtype and biomarker identification and many more.  

QIAGEN Biomedical Knowledge Base fuels QIAGEN Ingenuity Pathway Analysis (IPA), our premier ‘omics data analysis and interpretation software. This is data you know well, and now you can access it directly.  

“For over 20 years, we have been assembling the world’s leading source of molecular knowledge and data used to inform decisions from bench to bedside. This knowledge and data power market-leading products such as QIAGEN IPA, QIAGEN OmicSoft, QCI Interpret and online databases like HGMD and HSMD,” said Dr. Jonathan Sheldon, Senior VP of QIAGEN Digital Insights. “Previously, our focus was to make our knowledge and data solely accessible through our industry-leading applications. Now, in addition, we are unlocking and giving the keys to our knowledge and data to fuel drug discovery with data science. The data is in a format and structure that makes it easy to integrate our reliable molecular data into data science projects within pharma and biotech.” 

Using QIAGEN Biomedical Knowledge Base, you’ll make biomedical discoveries that are: 

  • High quality: Use accurate and industry-validated data. The data is produced using manual curation, including strict QC. It has been cited in tens of thousands of articles and used by leading organizations for more than 20 years. 
  • Novel: Explore and analyze integrated knowledge about causal biomedical relationships with full context to generate novel discoveries otherwise hidden among siloed and diverse data. 
  • Produced quickly and efficiently: Focus on answering questions, not collecting and cleaning data. Make discoveries in minutes using biomedical knowledge graph analysis, AI and more. 
  • Generated your way: Direct data access for flexible exploration and analysis. 

See how QIAGEN Biomedical Knowledge Base empowers you to leverage biomedical knowledge graph analysis, fuel your data- and analytics-driven drug discovery and transform your research. Learn more and request your trial today.